Clinical trials: Gastro-Intestinal Disorders
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Functional Constipation, Gastric Emptying
Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation
The purpose of this study is to assess the dose-related effects of TU-100, a botanical agent that modulates gastrointestinal nerves, on rectal compliance, rectal sensation thresholds and small bowel and colonic transit in female…
- Conditions
- Functional Constipation, Gastric Emptying, Whole Gut Transit, Small Bowel Transit
- Trial name
- NCT01139216
- Testing
- Daikenchuto (TU-100)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Tsumura USA
Gastroesophageal Reflux Disease
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using both GERD questionnaire and…
- Trial name
- NCT01432392
- Where
- 2 sites in Bulgaria
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
This PMS study had the objective to evaluate under ordinary medical care conditions the efficacy and tolerability of esomeprazole in patients who where treated by general practitioners and internists.
- Trial name
- NCT00567021
- Volunteers
- 67,130 people
- Sponsor
- AstraZeneca
Peptic Ulcer
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
- Trial name
- NCT06439563
- Testing
- JP-1366 10 mg, Lanston Capsule 15 mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Onconic Therapeutics Inc.
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term low-dose aspirin therapy will be investigated.
- Trial name
- NCT01568398
- Testing
- TAK-438
- Where
- 19 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Swallowing Disorders
NewBreez Safety and Efficacy Evaluation
The objective of this clinical study is to evaluate the safety and efficacy of the NewBreez intra-laryngeal implant in patients with dysfunctional larynx.
- Trial name
- NCT01587664
- Testing
- NewBreez ILP
- Where
- 2 sites in Belgium, France
- Volunteers
- 2 people
- Sponsor
- ProTiP Medical
Eosinophilic Esophagitis
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic…
- Trial name
- NCT02379052
- Testing
- Dupilumab
- Where
- 14 sites in United States
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Gastric Ulcer
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
The purpose of this study is to assess the efficacy of esomeprazole 20 mg dosed once daily and ranitidine 150 mg dosed twice daily through 4 weeks of treatment for the healing of gastric ulcers in patients receiving daily…
- Trial name
- NCT00401752
- Testing
- Esomeprazole, Ranitidine
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
Gastroparesis, Diabetic Gastroparesis
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus
- Trial name
- NCT00845858
- Testing
- metoclopramide
- Where
- 65 sites in United States
- Volunteers
- 287 people
- Sponsor
- Evoke Pharma
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Fatigue, Stress
The U.K. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE-UK (NCT05708963)
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- TMRW Life Sciences
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Regurgitation, Gastric
Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula
A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.
- Trial name
- Leopard (NCT03371615)
- Testing
- Anti-regurgitation infant formula
- Where
- 2 sites in Poland
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
- Trial name
- NCT02847455
- Testing
- 5 mg ilaprazole, 10 mg ilaprazole, 10 mg Rabeprazole
- Volunteers
- 408 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Gastroesophageal Reflux
SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)
The aim of this study is to evaluate the efficacy of a new thickened formula on regurgitation
- Trial name
- SWAN (NCT02710955)
- Testing
- Thickened infant formula
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- United Pharmaceuticals
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Reflux Oesophagitis
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.
- Trial name
- NCT01597674
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.